NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

CompletedN/A

Sponsor: AstraZeneca

Conditions: Anticoagulant-related Major Bleed

Interventions: Andexanet alfa, 4F-PCC

Countries: United States

This is an observational study based on data collected via an audit of electronic medical charts. The study population will include adult US patients treated with andexanet alfa or 4F-PCC during a hospitalization for an anticoagulation-related major bleed, and their characteristics, treatments and outcomes will be described.

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* ICD-10-CM diagnosis code of D68.32 (Hemorrhagic disorder due to extrinsic circulating anticoagulants) as part of an inpatient admission
* Taking either an oral FXa inhibitor or enoxaparin at the time of hospitalization for their bleeding event
* Treated with either andexanet alfa or 4F-PCC during the hospitalization for their bleeding event
* Had documented discharge disposition

Exclusion Criteria:

* Less than 18 years old
* Treated with both andexanet alfa and 4F-PCC during the hospitalization for their bleeding event

Locations (1)

Agoura Hills, California, United States